Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2012 June;64(2) > Minerva Urologica e Nefrologica 2012 June;64(2):143-8



A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


Minerva Urologica e Nefrologica 2012 June;64(2):143-8


Hepsin in the diagnosis of prostate cancer

Pace G. 1, 2, Pomante R. 3, Vicentini C. 1, 2

1 Department of Health Sciences, University of L’Aquila, L’Aquila, Italy;
2 Department of Urology, Mazzini Hospital, Teramo, Italy;
3 Department of Pathology, Mazzini Hospital, Teramo, Italy

AIM: In the current study we verified whether the expression of hepsin in prostate cancer (PCa) of samples obtained from radical retropubic prostatectomies (RRP) was significantly different from the adjacent normal prostatic tissue.
METHODS. We evaluate the expression of hepsin by using immunohistochemistry in PCa tissue in respect to the adjacent normal tissue, of 18 patients who underwent RRP.
RESULTS: Hepsin positive immunoreactivity was estimated on the staining intensity as negative (0), weakly positive (1+), moderately positive (2+), and strongly positive (3+). Hepsin immunoreactivity was detected in 100.0% PCa: 94.4% of cases showed a moderate/strong intensity, 5.6% a weak intensity. The adjacent benign prostatic tissue demonstrated a 83.3% of weak intensity, 11.1% had no reactivity and 5.6% were moderately intense. PCa demonstrated a significant higher (P<0.05) hepsin intensity (2.67) than the adjacent benign tissue (0.94).
CONCLUSION:Hepsin should be regarded as a novel potential immunohistochemical marker for the histopathological diagnosis of PCa.

language: English


top of page